At a glance
ClinicalIndex Comparison RecordN/ACompleted· 22 enrolled
Drug / intervention
Sitagliptin +1 moredrug
Likely dose
Glutamine 30g plus sitagliptin 100mgAI-extracted
Key inclusion· 1
- ✓Type 2 diabetes managed with metformin or diet alone
Key exclusion· 5
- ✕Malabsorption disorder
- ✕Renal disease
- ✕Liver disease
- ✕Current treatment with steroids
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
In the news
2 articles- STAT+: Medicare’s mum on GLP-1s, and Massachusetts sues UnitedSTAT News·2026-06-01
- <a href="https://www.fiercepharma.com/pharma/oral-glp-1-tracker-launch-trajectories-lilly-foundayo-novo-wegovy-pill" hreflang="en">The Oral GLP-1 Tracker: Amid Foundayo growing pains, Jefferies thinks blockbuster 1st year 'doable'</a>FiercePharma
Matched to this trial by ClinicalIndexfrom reputable biotech & medical press.
Study of the Effects of Glutamine on Glycemia, Glucagon-like Peptide-1 (GLP-1) and Insulin Secretion in Man
In Brief
A clinical study evaluating Sitagliptin and Placebo for Type 2 Diabetes. Completed, enrolled 22 participants across 1 site.
Detailed Summary
This study investigated the effect of glutamine, an amino acid, glycemia, glucagon-like peptide-1 (GLP-1) and insulin in participants with type 2 diabetes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
CountriesAustralia
Collaborators--
Timeline
N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2008
First PostedMay 2008
Primary CompletionDec 2011
Study CompletionNov 2014
TodayJul 2026
First PostedMay 7, 2008
Enrollment StartApr 1, 2008
Primary CompletionDec 1, 2011
Study CompletionNov 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 18.2 years ago
Interventions
Sitagliptindrug
Glutamine 30g +sitagliptin 100mg
Placebodrug
Glutamine 30g +placebo (matching sitagliptin 100 mg)